Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Elevar Therapeutics
HLB Takes First Expansion Step Via Immunomic Acquisition
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Elevar Aims For Rivoceranib Turnaround After Positive Phase III Update
Despite failing to meet the primary endpoint in recent top-line Phase III results, Elevar Therapeutics (formerly LSK BioPharma) is hopeful that rivoceranib still has potential in late-stage gastric cancer based on generally positive full efficacy data from the global Phase III study presented at ESMO.
LSKB Still Upbeat On Rivoceranib Despite ANGEL Failure In Late-Line Gastric Cancer
LSKB's rivoceranib has missed its endpoint in a Phase III trial in gastric cancer, but the company remains hopeful it will still be able to get FDA approval of the VEGFR-2 inhibitor in this setting, possibly helped by a small additional trial, although there will be a delay. Studies in other potential indications are also ongoing.
Deal Watch: Alexion Encouraged By RNAi Developments, Partners With Dicerna
Alexion thinks Dicerna’s RNAi technology could address complement-mediated conditions further upstream from antibodies like Soliris. AbbVie takes over CF collaboration with Galapagos, paying $45m up front.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.